期刊文献+

GSK3抑制剂氯化锂对脆性X综合征模型小鼠避暗行为的干预作用 被引量:2

Theraputic effects of lithium chloride on passive avoidance behavior in a mouse model of Fragile X Syndrome
下载PDF
导出
摘要 目的探讨糖原合成酶激酶3(glycogen synthase kinase3,GSK3)抑制剂氯化锂对脆性X综合症小鼠模型的避暗行为的干预作用及机制。方法通过对30日龄脆性X综合症小鼠连续腹腔注射不同剂量氯化锂5 d,用药第4天和第5天进行避暗实验;同时用免疫印迹技术检测Fmr1 knockout(KO)及wild type(WT)小鼠的海马和皮层总GSK 3β和磷酸化GSK 3β(P-GSK3β)的变化。结果在避暗实验中,KO鼠与WT鼠,两者潜伏期及错误次数分别为(56±32)s,(83±24)s;(7±3)次,(3±2)次;免疫印迹实验结果:KO鼠皮层及海马P-GSK3β表达平均灰度值分别为69,63;WT鼠皮层和海马均为100。注射氯化锂后,KO鼠和WT鼠总GSK3β无明显改变,而KO鼠60 mg/kg,120 mg/kg,200 mg/kg组皮层P-GSK3β表达平均灰度值分别为:147,151,234;海马P-GSK3β分别为108,111,146,较空白组增多;P<0.05。WT鼠用氯化锂后,潜伏期和错误次数以及P-GSK3β表达变化无统计学意义。结论氯化锂能改善KO鼠的学习记忆能力,可能与氯化锂导致的P-GSK3β的表达增加有关,对脆性X综合征基因敲除小鼠有治疗作用。 Objective To study the theraputic effects of lithium chloride on step-through behaviors and the activity of Glycogen Synthase Kinase 3β (GSK3β) in Fragile X Syndrome in mice. Methods Thirty-day-oht wild- type (WT) or Fmrl KO littermates received either normal saline or different doses of lithium chloride (30 mg/kg, 60 mg/kg, 90 mg/kg, 120 mg/kg or 200 mg/kg) for five consecutive days. Step-through testing was used to detect the latency period and error c, ount at 4 and 5 days following lithium treatment. Meanwhile, Western blot was used to ex- amine the expression of GSK3β and Phosphorylated GSK3β(P-GSK3β,) in mouse hippocampus and cortex. Results Compared with non-treated WT mice, non-treated KO mice had shorter latency period and more error counts in pas- sive avoidanee tests, suggesting that KO mice had learning and memory impairments. The expression level of phos- phoc,lated P-GSK3β) was lower in Fmrl KO than in WT mice. Lithium treatment could ceover the learning and memory impairments and increase the expression level of P-GSK3. Conclusions Lithium ameliorates passive avoid- ance impairment probably through increasing the expression of P-GSK3βin the Fmrl knockout mice.
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2012年第8期486-489,共4页 Chinese Journal of Nervous and Mental Diseases
基金 广东省自然科学基金项目(编号:815101700100005) 广东省科技计划项目(编号:2008B030301371 2009B030801368)
关键词 脆性X综合症FMR1基因敲除 避暗实验GSK3β 磷酸化GSK3β 氯化锂 Fragile X Syndrome Fmrl gene knockout mice Step-through test Glycogen synthase kinase3β Phosphorylated GSK3β Lithium Chloride
  • 相关文献

参考文献10

  • 1Garber K, Smith KT, Reines D, et al. Transcription, transla- tion and fragile X syndrome[J]. Curt Opin Genet Dev, 2006, 16(3) :270-275.
  • 2Crawford DE, Zhang F, Wilson B, et al. Fragile X CGG re- peat stnlctures among African-Americans: identification of a novel factor responsible for repeat instability [J]. Hum Mol Genet, 2000,9(12) : 1759-1769.
  • 3Min WW, Yuskaitis CJ, Yah Q, et al. Elevated glycogen syn- thase kinase-3 aclivity in Fragile X mice: key metabolic regula- tor with evidence for treatment potential[J]. Neuropharmacology, 2009,56(2) :463-472.
  • 4邢州,孙卫文,黄越玲,易咏红,戴丽军,陈盛强,李敏雄.采用PCR方法检测Fmr1基因敲除小鼠的基因型[J].现代医院,2009,9(5):12-14. 被引量:22
  • 5Berry-Kravis E, Sumis A, Hervey C, et al. Openlabel treatment trial of lithium to target the underlying defect in fragile X syn- drome[J ]. J Dev Behav Pediatr, 2008, 29(4):293-302.
  • 6Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psy- chiatric diseases and therapeutic interventions [J]. Curr Drug Targets, 2006,7( 11 ) : 1421-1434.
  • 7Jope RS. Anti-bipolar therapy: mechanism of action of lithium [J]. Mol Psychiatry, 1999,4(2) : 117-128.
  • 8Yuskaitis CJ, Mines MA, King MK, et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome [J]. Biochem Pharmacol, 2010,79 (4) : 632-646.
  • 9McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome[J]. Neuron, 2005,45 (5): 753-764.
  • 10Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation[J]. Trends Neurosci, 2004,27(7):370- 377.

二级参考文献11

  • 1WARREN S T.The epigenetics of fragile X syndrome[J].Cell Stem Cell,2007,1(5):488-489.
  • 2Fmr1 knockout mice:a model to study fragile X mental retardation.The Dutch-Belgian Fragile X Consortium[J].Cell,1994,78(1):23-33.
  • 3CRAWFORD D C,ACUA J M,SHERMAN S L.FMR1 and the fragile X syndrome:human genome epidemiology review[J].Genet Med,2001,3(5):359-371.
  • 4BAKKER,C E,OOSTRA B A.Understanding fragile X syndrome:insights from animal models[J].Cytogenet Genome Res,2003,100(1-4):111-123.
  • 5KOOY R F.Of mice and the fragile X syndrome[J].Trends Genet,2003,19(3):148-154.
  • 6HUBER K M,GALLAGHER S M,WARREN S T,et al.Altered synaptic plasticity in a mouse model of fragile X mental retardation[J].Proc Natl Acad Sci U S A,2002,99(11):7746-7750.
  • 7TODD P K,MACK K J,MALTER J S.The fragile X mental retardation protein is required for type-Ⅰmentabotropic glutamate receptor-dependent translation of PSD-95[J].Proc Natl Acad Sci U S A,2003,100(24):14374-14378.
  • 8HAGERMAN R J,HAGERMAN P J.Fragile X syndrome:a model of gene-brain-behavior relationships[J].Mol Genet Metab,2001,74(1-2):89-97.
  • 9O'DONNELL W T,WARREN S T.A decade of molecular studies of fragile X syndrome.Annu[J].Rev Neurosci,2002,25:315-338.
  • 10MINEUR Y S,SLUYTER F,DE WIT S,et al.Behavioral and Neuroanatomical Characterization of the Fmr1 Knockout Mouse[J].Hippocampus,2002,12(1):39-46.

共引文献21

同被引文献26

  • 1宋萍萍,王东信,王沛钰.利多卡因对不同载脂蛋白E基因型小鼠短暂全脑缺血后脑损害程度的影响[J].中华医学杂志,2005,85(48):3401-3408. 被引量:3
  • 2Jo J, Whitcomb DJ, Olsen KM, et al. Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Aktl and GSK-3β[J]. Nat Neurosci, 2011, 14(5): 545-547.
  • 3Zhao HH, Di J, Liu WS, et al. Involvement of GSK3 and PP2A in ginsenoside Rbl ' s attenuation of aluminum-induced tau hy- perphosphorylation[J]. Behav Brain Res, 2013, 241: 228-234.
  • 4Unal I, Gursoy-Ozdemir Y, Bolay H, et al. Chronic daily admin- istration of selegiline and EGb 761 increases brain's resistance to ischemia in mice[J]. Brain Res, 2001, 917(2): 174-181.
  • 5Hodges H, Nelson A, Virley D, et al. Cognitive deficits induced by global cerebral ischaemia: prospects for transplant therapy [J]. Pharmacol Biochem Behav, 1997, 56(4): 763-780.
  • 6Shibata M, Ohtani R, Ihara M, et al. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypo- perfusion[J]. Stroke, 2004, 35(11): 2598-2603.
  • 7Parker PJ, Caudwe|l FB, Cohen P. Glycogen synthase from rab- bit skeletal muscle; effect of insulin on the state of phosphoryla- tion of the seven phosphoserine residues in vivo[J]. Eur J Bio- chem, 1983, 130(1): 227-234.
  • 8Zhu YM, Wang CC, Chen L, et al. Both PI3K/Akt and ERK1/2 pathways participate in the protection by dexmedetomidine against transient focal cerebral ischemia/reperfusion injury in rats[J]. Brain Res, 2013, 1494: 1-8.
  • 9Ambacher KK, Pitzul KB, Karajgikar M, et al. The JNK- and AKT/GSK313-signaling pathways converge to regulate Puma in- duction and neuronal apoptosis induced by trophic factor depri- vation[J]. PLos One, 2012, 7(10): e46885.
  • 10刘萍.黄精多糖对老龄大鼠老化相关酶的影响[J].华西医学,2010,25(7):1259-1261. 被引量:16

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部